- Home
- VISN vs DNLI Comparison
VISN vs DNLI Comparison
Compare VISN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VISN | DNLI |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | United States |
| Employees | 20000 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | VISN | DNLI |
|---|---|---|
| Price | $17.65 | $21.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $31.20 |
| AVG Volume (30 Days) | ★ 3.3M | 1.5M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.12 | N/A |
| Revenue Next Year | $9.59 | $262.52 |
| P/E Ratio | $5.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.50 | $10.57 |
| 52 Week High | $19.91 | $23.77 |
Technical Indicators
Market Signals| Indicator | VISN | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 55.29 |
| Support Level | N/A | $13.29 |
| Resistance Level | $19.38 | $23.77 |
| Average True Range (ATR) | 0.85 | 1.19 |
| MACD | -0.17 | 0.04 |
| Stochastic Oscillator | 33.14 | 60.80 |
Price Performance
Historical ComparisonAbout VISN Vistance Networks Inc. Common Stock
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.